Moser Wealth Advisors LLC Buys Shares of 5,538 Novo Nordisk A/S (NYSE:NVO)

Moser Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 5,538 shares of the company’s stock, valued at approximately $573,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Pacific Center for Financial Services grew its stake in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Bell Investment Advisors Inc grew its holdings in Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the period. CNB Bank bought a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $26,000. Tyler Stone Wealth Management boosted its stake in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after acquiring an additional 146 shares during the period. Finally, West Paces Advisors Inc. raised its stake in Novo Nordisk A/S by 100.0% in the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after acquiring an additional 150 shares during the period. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. UBS Group assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Finally, BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded up $0.79 during trading on Thursday, reaching $127.48. 445,976 shares of the company’s stock were exchanged, compared to its average volume of 4,782,197. The firm’s 50-day moving average price is $127.33 and its 200 day moving average price is $113.50. The company has a market cap of $572.07 billion, a P/E ratio of 43.69, a PEG ratio of 1.93 and a beta of 0.43. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.